Literature DB >> 24852287

Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.

E Kanal1, K Maravilla2, H A Rowley3.   

Abstract

SUMMARY: The aim of this article was to review the properties of the various gadolinium-based contrast agents used for CNS imaging along with the clinical evidence and published data that highlight the impact these different properties can have on diagnostic performance. In addition, approaches to optimizing image acquisition that take into account the different properties of specific gadolinium-based contrast agents and an extensive review of the safety profiles of the various agents are presented.
© 2014 by American Journal of Neuroradiology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24852287      PMCID： PMC7965302          DOI： 10.3174/ajnr.A3917

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  71 in total

1.  Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

Authors:  Michael V Knopp; Val M Runge; Marco Essig; Marius Hartman; Olav Jansen; Miles A Kirchin; Albrecht Moeller; Astrid H Seeberg; Klaus-Peter Lodemann
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

2.  MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.

Authors:  W T Yuh; D J Fisher; J D Engelken; G M Greene; Y Sato; T J Ryals; M R Crain; J C Ehrhardt
Journal:  Radiology       Date:  1991-08       Impact factor: 11.105

3.  Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

Authors:  Mathias Prokop; Günther Schneider; Angelo Vanzulli; Mathias Goyen; Stefan G Ruehm; Philippe Douek; Massimo Daprà; Gianpaolo Pirovano; Miles A Kirchin; Alberto Spinazzi
Journal:  Radiology       Date:  2004-12-22       Impact factor: 11.105

4.  Role of thermodynamic and kinetic parameters in gadolinium chelate stability.

Authors:  Jean-Marc Idée; Marc Port; Caroline Robic; Christelle Medina; Monique Sabatou; Claire Corot
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

5.  Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.

Authors:  Kenneth R Maravilla; Joseph A Maldjian; Ilona M Schmalfuss; Matthew J Kuhn; Brian C Bowen; Franz J Wippold; Val M Runge; Michael V Knopp; Stephane Kremer; Leo J Wolansky; Nicoletta Anzalone; Marco Essig; Lars Gustafsson
Journal:  Radiology       Date:  2006-06-26       Impact factor: 11.105

6.  Brain MR perfusion imaging in humans.

Authors:  P D Griffiths; I D Wilkinson; T Wels; N Hoggard
Journal:  Acta Radiol       Date:  2001-11       Impact factor: 1.990

7.  Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study.

Authors:  Richard C Semelka; Mateus de A Hernandes; Clifton G Stallings; Mauricio Castillo
Journal:  Magn Reson Imaging       Date:  2012-08-13       Impact factor: 2.546

8.  Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.

Authors:  Frank G Shellock; John R Parker; Gianpaolo Pirovano; Ningyan Shen; Carol Venetianer; Miles A Kirchin; Alberto Spinazzi
Journal:  J Magn Reson Imaging       Date:  2006-12       Impact factor: 4.813

9.  Demonstration of an IgE-mediated immunological pathogenesis of a severe adverse reaction to gadopentetate dimeglumine.

Authors:  D Schiavino; F Murzilli; M Del Ninno; A Buonomo; C Roncallo; E Pollastrini; T De Pasquale; C Lombardo; E Nucera; G Patriarca
Journal:  J Investig Allergol Clin Immunol       Date:  2003       Impact factor: 4.333

10.  Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.

Authors:  P Akeson; E Jonsson; I Haugen; S Holtås
Journal:  Neuroradiology       Date:  1995-04       Impact factor: 2.804
View more
  22 in total

1.  Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Authors:  Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

2.  Label-Free Microfluidic Manipulation of Particles and Cells in Magnetic Liquids.

Authors:  Wujun Zhao; Rui Cheng; Joshua R Miller; Leidong Mao
Journal:  Adv Funct Mater       Date:  2016-04-14       Impact factor: 18.808

3.  In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents.

Authors:  Enrico Tedeschi; Giuseppe Palma; Antonietta Canna; Sirio Cocozza; Carmela Russo; Pasquale Borrelli; Roberta Lanzillo; Valentina Angelini; Emanuela Postiglione; Vincenzo Brescia Morra; Marco Salvatore; Arturo Brunetti; Mario Quarantelli
Journal:  Eur Radiol       Date:  2016-02-23       Impact factor: 5.315

4.  Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.

Authors:  Christian Funck-Brentano; Mathieu Felices; Nathalie Le Fur; Corinne Dubourdieu; Pierre Desché; Frédéric Vanhoutte; Pascal Voiriot
Journal:  Br J Clin Pharmacol       Date:  2020-04-27       Impact factor: 4.335

5.  The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study).

Authors:  M Vaneckova; M Herman; M P Smith; M Mechl; K R Maravilla; J Weichet; M V Spampinato; J Žižka; F J Wippold; J J Baima; R Babbel; E Bültmann; R Y Huang; J-H Buhk; A Bonafé; C Colosimo; S Lui; M A Kirchin; N Shen; G Pirovano; A Spinazzi
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-16       Impact factor: 3.825

6.  Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report.

Authors:  Einat Blumfield; Michael M Moore; Mary K Drake; Thomas R Goodman; Kristopher N Lewis; Laura T Meyer; Thang D Ngo; Christina Sammet; Arta Luana Stanescu; David W Swenson; Thomas L Slovis; Ramesh S Iyer
Journal:  Pediatr Radiol       Date:  2017-03-10

Review 7.  Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.

Authors:  Dragan Stojanov; Aleksandra Aracki-Trenkic; Daniela Benedeto-Stojanov
Journal:  Neuroradiology       Date:  2016-02-12       Impact factor: 2.804

8.  Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.

Authors:  D S Enterline; K W Martin; H A Parmar; F M Triulzi; C Colosimo
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

9.  Effects of gadolinium-based contrast agents on submandibular gland tissue in rats.

Authors:  Fatma Beyazal Celiker; Levent Tumkaya; Adnan Yilmaz; Zerrin Ozergin Coskun; Metin Celiker; Fatih Oghan; Tolga Mercantepe; Suat Terzi; Engin Dursun
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-31       Impact factor: 2.503

10.  Interstudy repeatability of self-gated quantitative myocardial perfusion MRI.

Authors:  Devavrat Likhite; Promporn Suksaranjit; Ganesh Adluru; Nan Hu; Cindy Weng; Eugene Kholmovski; Chris McGann; Brent Wilson; Edward DiBella
Journal:  J Magn Reson Imaging       Date:  2015-12-13       Impact factor: 4.813
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.